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BACKGROUND. The identification of prognostic factors in the recurrence of vulvar
squamous cell carcinoma is crucial for less invasive treatments.
METHODS. The authors studied 101 patients treated for primary invasive squamous
cell carcinoma of the vulva. Selected pathologic variables were observed in a
standardized manner during treatment, and their association with disease free
survival was investigated using the Cox model. Independent prognostic factors
were selected by a stepwise procedure. The absolute survival of patient groups
determined on the basis of such factors was computed by the product limit
method.
RESULTS. The median follow-up was 3.1 years (range, 56 days to 15.5 years).
Recurrences developed in 33 patients. The independent recurrence predictors
were as follows: International Federation of Gynecology and Obstetrics (FIGO)
Stage IVA (vs. IB, II, or III) (risk ratio [RR]adjusted for other independent factors,
7.39), tumor multifocality (RR, 4.10), lymphovascular space involvement (LVSI)
(RR, 2.96), the presence of associated vulvar intraepithelial neoplasia (VIN) Grade
2 or 3 (RR, 3.34), and the involvement of resection margins (RR, 4.88). By ignoring
the FIGO stage and lymph node status, the independent predictors were then as
follows: greatest tumor dimension , 2.5 cm, 2.5– 4 cm (RR, 2.86), or . 4 cm (RR,
5.98); tumor multifocality (RR, 3.36); LVSI (RR, 4.19); the presence of VIN 2 or 3 (RR,
3.06); and the involvement of surgical margins (RR, 2.78). No recurrences were
observed in 119 at-risk years among patients with unifocal tumors , 2.5 cm in
greatest dimension, free surgical margins, no LVSI, and no associated VIN 2 or 3.
CONCLUSIONS. The presence of associated VIN 2 or 3 was revealed to be a previ-
ously unidentified independent prognostic factor for recurrence. Subjects at low
risk of recurrence could be identified even without consideration of lymph node
status. Cancer 2000;88:1869 –76. © 2000 American Cancer Society.
KEYWORDS: vulvar neoplasm pathology, neoplasm recurrence, multivariate analy-
sis, treatment outcome.
Over the last 2 decades, improvements in understanding the prog-nostic factors for vulvar squamous carcinoma have led to a reex-
amination of the application of total radical vulvectomy with bilateral
inguinofemoral lymphadenectomy as the standard therapy for
women affected by this disease.1 Less invasive treatments with lower
morbidity and fewer psychosexual consequences are appropriate
nowadays for some groups of patients, even if concern about the
increased risk of recurrence with conservative approaches suggests
caution.2
In the relatively few studies on recurrent vulvar carcinoma, dif-
ferent methodologic approaches and statistical analyses were em-
ployed to investigate the role of clinicopathologic parameters in pre-
dicting disease free survival. A clear definition of the terms employed
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in these studies was often omitted, hence accounting
for the difficulty in comparing results.
In a previous study3 we found that greatest tumor
dimension and lymphovascular space involvement
(LVSI) could actually predict the probability of lymph
node metastases with reasonably good precision.
This study was designed to evaluate different clin-
icopathologic features as independent prognostic fac-
tors and to identify groups of women at low risk of
recurrence, in particular considering prognostic fac-
tors not involving lymph node status.
MATERIALS AND METHODS
Study subjects were patients treated for vulvar malig-
nancies at the Department of Gynecology and Obstet-
rics, University of Turin, Turin, Italy, from January 1,
1982, through December 31, 1996.
Eligibility criteria were as follows:
● Histologic diagnosis of epidermoid carcinoma (8 pa-
tients were excluded, 7 with verrucous carcinomas
and 1 with an adenocarcinoma of the Bartholin
gland);
● Diagnosis of primary vulvar carcinoma (6 patients
with recurrent carcinoma were excluded);
● Depth of stromal invasion . 1 mm, measured from
the most superficial adjacent dermal papillae to the
deepest point of invasion4 (8 patients with Interna-
tional Federation of Gynecology and Obstetrics
[FIGO] Stage IA5 T1aN0M0 tumor confined to the
vulva or vulva and perineum, 2 cm or less in greatest
dimension, with stromal invasion no greater than 1
mm,6 were excluded);
● No recurrence during the first month after surgery (2
patients with shorter disease free survival were ex-
cluded);
● No previous malignancy and no associated malig-
nancy diagnosed at the time of the operation (no
cases were excluded);
● Total and bilateral inguinofemoral lymphadenec-
tomy (11 patients were excluded to ensure homoge-
neity and comparability: 5 not total, 6 not bilateral).
Among the 136 patients treated during the rele-
vant period, 101 were eligible and entered the study.
This series included 50 patients who were studied
previously with respect to predictive factors for lymph
node metastases.3
All the women gave informed written consent to
therapeutic procedures and the analysis of clinico-
pathologic data related to their malignancy in accor-
dance with local institutional guidelines and the
Treaty of Helsinki.
Stages were defined according to the 1994 FIGO
staging system5 and the American Joint Committee on
Cancer (AJCC) TNM classification.6
Patients were treated with a total deep vulvectomy
or a partial deep vulvectomy with the deep fascia of
the urogenital diaphragm as the depth limit of the
resection.7 An attempt was made to obtain 1.5 cm of
macroscopically free surgical margins. Almost all op-
erations prior to 1989 consisted of a vulvectomy and
lymphadenectomy using a single en bloc incision.
Subsequently, there was an increase in the use of three
separate skin incisions: one over each groin, the third
being the vulvectomy incision. This technique was not
used on patients with clinically suspicious inguinal
lymph nodes or with sufficiently extensive primary
lesions that implied a risk of inadequate margins.
A total bilateral inguinofemoral lymphadenec-
tomy with the preservation of the fascia femoralis
included the superficial inguinal lymph nodes, the
superficial femoral lymph nodes, and the deep ingui-
nal or deep femoral lymph nodes. Surgery was per-
formed as a single procedure on all patients.
Radiotherapy was given to all patients with 3 or
more positive inguinal lymph nodes, with irradiation
of the groin and the pelvis varying from 45 to 55 grays
over a period of 4 –5 weeks. No patients other than
those just described were submitted to radiotherapy
before a recurrence appeared. No chemotherapy was
provided to any patient included in this series.
Patients received regular follow-up. Checkups
were scheduled every 3 months during the first 2
years, every 6 months for the subsequent 3 years, and
then once every 12 months. An appointment for the
next checkup was made during each checkup. Check-
ups were also carried out at patient request. Women
who did not show up at a scheduled checkup were
reminded by telephone. Whenever it was not possible
to find a woman, an effort was made to contact her
relatives. Most patients exhibiting severe illness, even
when different from recurrence, were referred to our
unit or we were asked for a consultation. We could
therefore assess cancer recurrence directly, if present,
just before death, even in patients dying from causes
other than vulvar carcinoma. In a few cases where this
was not possible, the doctors in charge of the women’s
care were contacted and the medical records con-
sulted.
No distinction between recurrence and reoccur-
rence was made. If the first recurrence occurred in
more than one site, the patient was assigned to a
group on the basis of the most advanced level of
disease involvement (vulva , lymph nodes , dis-
tant).
The recurrence free interval was computed as the
time from the day of surgery (admission date) to the
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discharge date, i.e., the moment of evidence of disease
recurrence, or the end of the follow-up period. In
operational terms, the discharge date was taken to be
the date of the last checkup for women with no evi-
dence of recurrence. The study ended on June 2, 1997.
Where checks were performed after that date, only the
period until June 2, 1997, was considered for the fol-
low-up. For women who died without recurrence, the
discharge date was defined as the date of death. We
could not assess whether recurrence was present in
only one patient who died. She was considered as
having exited the study without recurrence at the date
of her last checkup.
All surgical specimens were sectioned in the same
standardized manner.8 An average of 7 blocks of the
primary lesion and 12 blocks of the inguinal lymph
nodes were examined.
The predictive variables considered were FIGO
stage,5 pT classification6, patient age, greatest tumor
dimension, tumor focality, depth of stromal invasion,4
number of metastatic lymph nodes, koilocytosis
within the tumor tissue, tumor necrosis, pattern of
tumor invasion, lymphovascular space involvement,
perineural space involvement, vulvar intraepithelial
neoplasia (VIN) Grade 2 or 3 in tissue adjacent to the
invasive tumor,4 nonneoplastic epithelial disorders
and superficially invasive carcinoma adjacent to the
invasive tumor,4 status of resection margins (positive
when tumoral cells were found within 3 mm of the
resection perimeter), type of vulvar surgery (total deep
vulvectomy or partial deep vulvectomy), type of skin
incision (single or triple), and distal uretrectomy.
Statistical Methods
The main study outcome was disease free survival. It
was computed for the entire group by the Kaplan–
Meier method.9 Determinants of disease free survival
were studied by using the Cox proportional hazards
model.9 Subjects with missing values for any of the
variables were considered part of a separate category.
For each variable P values were computed on the basis
of Wald x2. If a variable could assume more than two
values, then a likelihood ratio (LR) x2 was also com-
puted for the overall effect.10 Variables were consid-
ered in both the univariate analysis and after adjust-
ment for the FIGO stage. This is an established
prognostic factor and was found to be the most im-
portant predictor of disease free survival in our study.
Independent prognostic factors were selected by a
stepwise procedure. In order to evaluate whether it
was possible to select a low risk group without con-
sidering groin lymph node status, the same procedure
was repeated with the FIGO stage and the number of
involved lymph nodes excluded. Study women were
grouped into subpopulations on the basis of selected
variables, and absolute disease free survival was com-
puted for each subpopulation by the Kaplan–Meier
method.
RESULTS
The 101 patients were followed for a median of 3.1
years (range, 56 days to 15.5 years). Among study
patients, 63% either had a recurrence or were followed
for at least 5 years, and 76% were followed for at least
3 years. Among the 68 women in whom no recurrence
was documented, 8 died of intercurrent causes, 41 had
their last checkup within 6 months of the end of the
study, and 13 more had their last checkup within 12
months. All women in the latter group were followed
for at least 3 years. The remaining 6 women had their
last checkup more than 18 months before the end of
the study and were considered lost to follow-up. How-
ever, 4 of them were followed for at least 3 years.
Of 101 patients, 33 developed recurrences. One
patient had a lymph node recurrence 2 months after
the initial therapy. All the remaining patients had re-
currence 3–127 months following surgery (median,
9.13 months).
Recurrence was vulvar in 18 patients, nodal in 11,
and distant in 4. Multiple failure sites were noted in
seven patients (vulvar and nodal recurrence in six,
vulvar and distant in one). Fifteen of the 18 vulvar
recurrences were on the same side of the primary
neoplasm. With respect to distant recurrences (two
bone and two lung metastases), all four patients had
LVSI in their primary tumor, suggesting hematoge-
nous spread.
Disease free survival probability at 1, 2, 3, and 5
years in the overall study population was 79.7%,
76.1%, 70.8%, and 66.2%, respectively (Fig. 1).
In univariate analysis (Table 1), FIGO stage, pT
classification, greatest tumor dimension, multifocal-
ity, depth of stromal invasion, number of metastatic
lymph nodes, presence of koilocytosis, LVSI, and the
presence of associated VIN 2 or 3 were statistically
associated with shorter disease free survival (P ,
0.05). The presence of tumor necrosis and the involve-
ment of surgical resection margins reached borderline
significance.
After adjustment for the FIGO stage (Table 1), only
tumor multifocality, the presence of koilocytosis, LVSI,
and the presence of associated VIN 2 or 3 maintained
independent effects. On the other hand, tumor necro-
sis and the involvement of surgical margins turned out
to be significantly associated with shorter disease free
survival, and neural invasion reached borderline sig-
nificance.
FIGO Stage IVA (vs. IB, II, or III), tumor multifo-
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cality, LVSI, the presence of VIN 2 or 3, and the in-
volvement of resection margins were independent
predictors of recurrence as based on stepwise model
selection (Table 2). When a stepwise procedure was
repeated while FIGO stage and lymph node status was
ignored (Table 3), then greatest tumor dimension
(, 2.5 cm, 2.5– 4 cm, and . 4 cm), tumor multifocal-
ity, LVSI, the presence of associated VIN 2 or 3, and the
involvement of surgical margins were selected as in-
dependent predictors.
When considering the type of vulvar surgery, the
88 patients treated by total deep vulvectomy showed
no reduction in the risk of recurrence after adjustment
for FIGO stage and the other independent prognostic
factors. The same was observed in the 10 subjects who
underwent distal urethrectomy. On the other hand,
after adjustment for all independent risk factors, the
69 patients who had a single en bloc incision had a
significantly lower relapse rate than the 32 patients
who had a triple skin incision. This was true both after
adjustment for variables in Table 2 (RR 5 0.35, P 5
0.032) and after adjustment for variables in Table 3
(RR 5 0.37, P 5 0.032). Adjustment for surgical tech-
nique variables only slightly changed the effect of the
other clinicopathologic variables.
The group of patients with unifocal tumors of
greatest dimension , 2.5 cm, no LVSI, no associated
VIN 2 or 3, and no involvement of surgical margins
(Group 1) comprised 16 patients and was followed for
an average of 7.5 years. No recurrence was observed
among them. Survival was, however, still high (Fig. 2)
if greatest tumor dimension was still , 2.5 cm and
there was no LVSI, even if the remaining criteria re-
lapsed: 3 of these 16 subjects recurred (Group 2). On
the other hand, 5-year disease free survival was 52%
among women with greatest tumor dimension be-
tween 2.5 and 4 cm or LVSI: 22 of these 56 subjects had
recurrence (Group 3), and 1-year disease free survival
was only 42% among patients with greatest tumor
dimension . 4 cm: 8 of these 13 subjects had recur-
rence (Group 4). Disease free survival was as low as
28.9% after 1 year in FIGO Stage IVA patients.
In Groups 1 and 2, lymph node involvement was
present in 2 women and 1 woman, respectively, with-
out capsular involvement in any of these cases.
DISCUSSION
This study was based on a series of patients in which
a number of pathologic variables was measured sys-
tematically at treatment by the same pathologist
(G.B.). In addition, the surgical technique was stan-
dardized and nonsurgical treatments were homoge-
neous. The duration of follow-up was long and the
number of patients lost to follow-up very limited. Al-
though the number of patients was not very large in
absolute terms, it represents one of the largest series
of this rare cancer currently studied at a single insti-
tution.
Only patients achieving free status were included
in order to avoid confusion between residual and re-
current cancer. On the other hand, we did not discern
recurrence from reoccurrence because the interval be-
tween a primitive carcinoma and the posttreatment
appearance of a second vulvar invasive carcinoma is
defined ambiguously in the literature.
The FIGO staging classification is based on tumor
size and adjacent spread, lymph node involvement,
and the presence of any distant metastases.5 It is
known to be the most important prognostic criterion
for vulvar carcinoma, as confirmed in studies with
FIGURE 1. Disease free survival (with
95% CI) is shown for the entire study
population.
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TABLE 1
Relative Disease Free Survival after Surgery for Vulvar Carcinoma: Effect of Studied Potential Determinants in Univariate Analysis
and after Adjustment for FIGO Stage Classification
Parameter







FIGO stage/AJCC TNMa (LR x2 3df 5 20.86, P , 0.0001)
IB/T1bN0M0 7/34 1
II/T2N0M0 8/25 1.59 0.37
III/T3N0M0, T1–3N1M0 5/18 1.61 0.42
IVA/T1–3N2M0 13/24 8.03 , 0.0001
pT classification (LR x2 2df 5 12.95, P , 0.005) (LR x
2
2df 5 2.87, P . 0.05)
1 9/41 1 1
2 19/54 2.24 0.047 1.59 0.46
3 5/6 9.53 , 0.0001 3.63 0.11
Greatest tumor dimension (cm) (LR x2 3df 5 14.22, P , 0.005) (LR x
2
3df 5 2.44, P . 0.05)
# 1.5 8/34 1 1
. 1.5–2.5 5/24 0.96 0.94 0.82 0.76
. 2.5–4 12/30 2.96 0.019 1.89 0.40
. 4 8/13 5.16 0.0011 1.89 0.45
Tumor focality
Unifocal 19/79 1 1
Multifocal 14/22 2.90 0.0027 2.79 0.0044
Depth of stromal invasion (mm) (LR x24df 5 11.13, P , 0.05) (LR x
2
4df 5 4.02, P . 0.05)
#3 7/23 1 1
. 3–5 4/22 0.76 0.76 0.70 0.59
. 5–9 8/21 1.69 0.31 0.96 0.94
. 9 9/17 4.01 0.006 1.90 0.27
Missing 5/18 0.89 0.84 0.69 0.54
No. of metastatic lymph nodes (LR x24df 5 17.18, P , 0.025) (LR x
2
4df 5 0.796, P . 0.05)
0 16/62 1 1
1 2/8 0.92 0.88 0.55 0.62
2 4/9 3.79 0.0202 1.07 0.96
3–5 8/15 4.46 0.0002 0.95 0.97
. 5 3/7 8.10 0.0014 1.32 0.84
Koilocytosis
Absent 25/88 1 1
Present 8/13 2.96 0.0083 4.00 0.0017
Tumor necrosis
Absent 25/87 1 1
Present 8/14 2.19 0.055 2.34 0.042
LVSI
Not evident 10/52 1 1
Evident 23/49 3.99 0.0005 3.09 0.0095
Neural invasion
Not evident 28/88 1 1
Evident 5/13 2.15 0.12 2.72 0.054
Association of VIN 2 or 3
Absent 19/74 1 1
Present 14/27 2.30 0.019 3.37 0.0018
Surgical resection margins
Negative 27/91 1 1
Positive 6/10 2.44 0.052 4.09 0.0055
FIGO: International Federation of Gynecology and Obstetrics; AJCC: American Joint Committee on Cancer; LR: likelihood ratio; LVSI: lymphovascular space involvement; VIN: vulvar intraepithelial neoplasia.
a Definition of TNM:6 T1b: tumor confined to the vulva or vulva and perineum, 2 cm or less in greatest dimension, with stromal invasion greater than 1 mm; T2: tumor confined to the vulva or vulva and perineum,
more than 2 cm in greatest dimension; T3: tumor of any size with adjacent spread to the lower urethra and/or vagina or anus; N0: no regional lymph mode metastasis; N1: unilateral regional lymph node metastasis;
N2: bilateral regional lymph node metastasis; M0: no distant metastasis.
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multivariate statistical analysis. Identifying other in-
dependent prognostic factors is, however, relevant in
order to understand better the natural history of vul-
var carcinoma and to select subgroups of patients at
low risk of recurrence and suitable for a less aggressive
surgical approach. In our study, tumor multifocality,
LVSI, associated VIN 2 or 3, and involvement of sur-
gical margins were actually independent predictors of
recurrence.
Multifocality of neoplastic lesion, occurring in
about 25% of invasive carcinomas (22% in our series),
was already reported as associated with local recur-
rences.11 Our data did not support the evidence that in
multifocal cancers surgical margins are positive more
frequently than in unifocal cancers:11 only 1 of 22
multifocal tumors had positive margins versus 9 of 79
unifocal tumors. In addition, multifocality maintains
its effect even after adjustment for the involvement of
surgical margins (Table 3). Therefore other mecha-
nisms are involved.
The association of LVSI with an increase in fre-
quency of lymph node involvement was first reported
by Donaldson12 and confirmed in a large series of the
Gynecologic Oncology Group.13 In our data, the pres-
ence of LVSI increased slightly (though statistically not
significantly) from vulvar recurrences (12/18) to
lymph node (8/11) and distant (4/4) recurrences.
To our knowledge, our study is the first to report
adjacent VIN 2 or 3 as a significant independent pre-
dictor of reduced disease free survival in multivariate
analysis. Among the 14 cases of recurrence associated
with VIN 2 or 3, 7 were vulvar recurrences, 5 lymph
node recurrences, and 2 distant recurrences. At vari-
ance is another recent study14 that found better dis-
ease free and overall survival of cases associated with
VIN 3 when compared (without adjustment for other
factors) with cases associated with lichen sclerosus.
We found koilocytosis to be a significant prognostic
factor after adjustment for FIGO staging, but it did not
show an independent effect in the final model. In our
data, koilocytosis in invasive carcinoma was strongly
associated with the presence of VIN 2 or 3 in adjacent
lesions: indeed, koilocytosis was present in 10 of 27
cases with associated VIN 2 or 3 and in only 3 of 74
cases without VIN 2 or 3 (OR 5 10.4, P , 0.0001).
Therefore, it behaved mainly as an indicator of asso-
ciated VIN 2 or 3 presence. The clinical significance of
HPV infection in vulvar carcinoma has not been well
established and results regarding its prognostic signif-
icance are conflicting.
The involvement of surgical resection margins is
frequently reported in association with local relapses.
The recurrence rate is higher when tumor free margins
are less than 1 cm11,15 without correlation with the
type of vulvar surgery (modified wide radical vulvar
excision vs. total radical vulvectomy).16 In our series,
neither patients treated with deep total vulvectomy
nor those who underwent distal urethrectomy showed
a significant reduction in the risk of recurrence after
adjustment for the FIGO stage. On the other hand, we
found an increased risk of relapse for triple incision,
TABLE 3
Relative Disease Free Survival after Surgery for Vulvar Carcinoma:
Independent Determinants when Ignoring FIGO Stage and Lymph
Node Status (Stepwise Model Selection)
Determinant Risk ratioa Specific P value (Wald)
Greatest tumor dimension (cm)
, 2.5 1
2.5–4 2.86 0.0129






Not evident 4.19 0.0005






LVSI: lymphovascular space involvement; VIN: vulvar intraepithelial neoplasia.
a Each risk ratio is adjusted for the other variables in this table.
TABLE 2
Relative Disease Free Survival after Surgery for Vulvar Carcinoma:
Independent Determinants (Stepwise Model Selection)
Determinant Risk ratioa Specific P value (Wald)
FIGO stage














FIGO: International Federation of Gynecology and Obstetrics; LVSI: lymphovascular space involvement;
VIN: vulvar intraepithelial neoplasia.
a Each risk ratio is adjusted for the other variables in this table.
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after adjustment for the other independent prognostic
factors. However, no relapse in this group occurred on
the skin bridge preserved between the vulvar and
groin incisions. In any case, this study was not de-
signed to assess the effectiveness of different surgical
techniques: a randomized trial would be more appro-
priate. Other observational studies have reported the
risk of recurrence as not being altered by the type of
incision,17 with no drop in the overall cure rate for
triple incision.18 However, uncertainty remains re-
garding patients with positive inguinal lymph nodes
treated with separate incisions.17
We considered tumor size and lymph node me-
tastases in greater detail than FIGO staging does, but
we found no independent effect after adjustment for
the FIGO stage itself. Therefore, our study does not
allow us to state that such further detail adds prog-
nostic value.
We defined groups at different risks of relapse on
the basis of our analysis. Our purpose, when comput-
ing their survival, was not to confirm a difference (as
this was for the same subjects, it would have been
tautological), but to obtain absolute risk estimates.
Actually, these are interesting for patients and clini-
cians in the context of deciding the most appropriate
treatment. Even when we used prognostic criteria that
did not require lymphadenectomy to be verified, we
identified a subpopulation of patients at an extremely
low risk of recurrence (Group 1) and another at favor-
able prognosis (Group 2). This was in agreement with
our previous finding that lymph node involvement
could be predicted by tumor size and the presence of
vascular invasion.3 Such low risk subpopulations rep-
resent a nonnegligible proportion of vulvar carcinoma
patients (in our series, about one subject out of three
belonged to either group) and are therefore of sub-
stantial clinical interest.
Our findings could suggest the initial treatment of
all patients by relatively conservative surgery. If, based
on the results of such initial surgery, the woman is
classified in a low risk group, then treatment could
stop, whereas more radical intervention could follow
in high risk subjects. The prediction of groin lymph
node involvement by other pathologic criteria is, nev-
ertheless, not completely precise. Indeed, more than
10% of cases in Group 1 had lymph node involvement.
In such cases we cannot presume a favorable progno-
sis in the absence of a lymphadenectomy. Indeed, in
previous studies in which an attempt to reduce the
radicality in the surgical approach to the groin was
made, an increased recurrence rate with subsequent
high mortality rate was reported.2,19
Therefore, we still believe that total bilateral in-
guinofemoral lymphadenectomy is the standard ap-
proach to treating invasive vulvar carcinoma. How-
ever, given the a priori low risk of lymph node
involvement and recurrence, patients belonging to
Groups 1 and 2 could be candidates for a trial to
evaluate more conservative inguinal surgery based on
the recent results from sentinel lymph node lympho-
scintigraphy technology.20
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